Early acute antibody-mediated rejection of a negative flow crossmatch 3rd kidney transplant with exclusive disparity at HLA-DP

Human Immunology

Volumn 75, Issue 8, 2014, Pages 703-708

  Mierzejewska, Beata ^a   Schroder, Paul M ^a   Baum, Caitlin E ^a   Blair, Annette ^a   Smith, Connie ^a   Duquesnoy, Rene J ^b   Marrari, Marilyn ^b   Gohara, Amira ^a   Malhotra, Deepak ^a   Kaw, Dinkar ^a   Liwski, Robert ^c   Rees, Michael A ^a   Stepkowski, Stanislaw ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Antibody mediated rejection; Donor specific antibodies; Epitopes; Flow cytometry crossmatch; Kidney transplantation

Indexed keywords

ALEMTUZUMAB; COMPLEMENT COMPONENT C1Q; CYCLOSPORIN; HLA DP ANTIGEN; IMMUNOGLOBULIN G1 ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; ALLOANTIBODY; COMPLEMENT C4D; COMPLEMENT COMPONENT C4B; HLA DRB3 ANTIGEN; HLA-DPA1 ANTIGEN; HLA-DPB1 ANTIGEN; PEPTIDE FRAGMENT;

ACUTE GRAFT REJECTION; ADULT; ANALYTIC METHOD; ANTIBODY MEDIATED REJECTION; ARTICLE; BLOOD GROUP TYPING; BLOOD TRANSFUSION; CASE REPORT; CHRONIC GRAFT REJECTION; END STAGE RENAL DISEASE; FEMALE; HLA MATCHING; HLA TYPING; HUMAN; IMMUNIZATION; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LIVING DONOR; PRIORITY JOURNAL; PYELONEPHRITIS; REFLUX NEPHROPATHY; RENAL REPLACEMENT THERAPY; SINGLE ANTIGEN BEAD ANALYSIS; BIOSYNTHESIS; GRAFT REJECTION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; METABOLISM; PATHOLOGY; UNRELATED DONORS; YOUNG ADULT;

COMPLEMENT C1Q; COMPLEMENT C4B; FEMALE; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HLA-DP ALPHA-CHAINS; HLA-DP ANTIGENS; HLA-DP BETA-CHAINS; HLA-DRB3 CHAINS; HUMANS; ISOANTIBODIES; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PEPTIDE FRAGMENTS; UNRELATED DONORS; YOUNG ADULT;

EID: 84905115412     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2014.04.001     Document Type: Article

References (27)

1. Couzi L., Araujo C., Guidicelli G., Bachelet T., Moreau K., Morel D., et al. Interpretation of positive flow cytometric crossmatch in the era of the single-antigen bead assay. Transplantation 2011, 91:527-535.
2. Mohan S., Palanisamy A., Tsapepas D., Tanriover B., Crew R.J., Dube G., et al. Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol 2012, 23:2061-2071.
3. Patel A.M., Pancoska C., Mulgaonkar S., Weng F.L. Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 2007, 7:2371-2377.
4. Gupta A., Iveson V., Varagunam M., Bodger S., Sinnott P., Thuraisingham R.C. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant?. Transplantation 2008, 85:1200-1204.
5. Hirai T., Kohei N., Omoto K., Ishida H., Tanabe K. Significance of low-level DSA detected by solid-phase assay in association with acute and chronic antibody-mediated rejection. Transpl Int 2012, 25:925-934.
6. Vlad G., Ho E.K., Vasilescu E.R., Colovai A.I., Stokes M.B., Markowitz G.S., et al. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum Immunol 2009, 70:589-594.
7. Aubert V., Venetz J.P., Pantaleo G., Pascual M. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol 2009, 70:580-583.
8. Vaidya S., Hilson B., Sheldon S., Cano P., Fernandez-Vina M. DP reactive antibody in a zero mismatch renal transplant pair. Hum Immunol 2007, 68:947-949.
9. Rosenberg W.M., Bushell A., Higgins R.M., Wordsworth B.P., Wood K.J., Bell J.I., et al. Isolated HLA-DP mismatches between donors and recipients do not influence the function or outcome of renal transplants. Hum Immunol 1992, 33:5-9.
10. Mytilineos J., Deufel A., Opelz G. Clinical relevance of HLA-DPB locus matching for cadaver kidney retransplants: a report of the Collaborative Transplant Study. Transplantation 1997, 63:1351-1354.
11. Jolly E.C., Key T., Rasheed H., Morgan H., Butler A., Pritchard N., et al. Preformed donor HLA-DP-specific antibodies mediate acute and chronic antibody-mediated rejection following renal transplantation. Am J Transplant 2012, 12:2845-2848.
12. Singh P., Colombe B.W., Francos G.C., Martinez Cantarin M.P., Frank A.M. Acute humoral rejection in a zero mismatch deceased donor renal transplant due to an antibody to an HLA-DP alpha. Transplantation 2010, 90:220-221.
13. Tambur A.R., Buckingham M., McDonald L., Luo X. Development of donor-specific and non-donor-specific HLA-DP antibodies post-transplant: the role of epitope sharing and epitope matching. Clin Transpl 2006, 399-404.
14. Muczynski K.A., Ekle D.M., Coder D.M., Anderson S.K. Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: characterization, isolation, and regulation of MHC class II expression. J Am Soc Nephrol 2003, 14:1336-1348.
15. Lawrence C., Willicombe M., Brookes P.A., Santos-Nunez E., Bajaj R., Cook T., et al. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts. Transplantation 2013, 95:341-346.
16. Callender C.J., Fernandez-Vina M., Leffell M.S., Zachary A.A. Frequency of HLA-DP-specific antibodies and a possible new cross-reacting group. Hum Immunol 2012, 73:175-179.
17. Billen E.V., Christiaans M.H., Doxiadis I.I., Voorter C.E., van den Berg-Loonen E.M. HLA-DP antibodies before and after renal transplantation. Tissue Antigens 2010, 75:278-285.
18. Thaunat O., Hanf W., Dubois V., McGregor B., Perrat G., Chauvet C., et al. Chronic humoral rejection mediated by anti-HLA-DP alloantibodies: insights into the role of epitope sharing in donor-specific and non-donor specific alloantibodies generation. Transpl Immunol 2009, 20:209-211.
19. Ciubotariu R., Liu Z., Colovai A.I., Ho E., Itescu S., Ravalli S., et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 1998, 101:398-405.
20. Vanderlugt C.L., Begolka W.S., Neville K.L., Katz-Levy Y., Howard L.M., Eagar T.N., et al. The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Immunol Rev 1998, 164:63-72.
21. Suciu-Foca N., Harris P.E., Cortesini R. Intramolecular and intermolecular spreading during the course of organ allograft rejection. Immunol Rev 1998, 164:241-246.
22. Bodmer J., Bodmer W., Heyes J., So A., Tonks S., Trowsdale J., et al. Identification of HLA-DP polymorphism with DP alpha and DP beta probes and monoclonal antibodies: correlation with primed lymphocyte typing. Proc Natl Acad Sci USA 1987, 84:4596-4600.
23. Drover S., Codner D., Gamberg J., Hutchings L., Marshall W.H. A site-specific anti-HLA-DP monoclonal antibody recognizes molecules bearing "DE" at positions 55 and 56 on the beta chain. Tissue Antigens 1991, 38:37-40.
24. Duquesnoy R.J., Awadalla Y., Lomago J., Jelinek L., Howe J., Zern D., et al. Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR, DQ, DP epitopes. Transpl Immunol 2008, 18:352-360.
25. Youngs D. HLA-DP alloantibodies. ASHI Q 2004, 28:60-62. (Ref Type: Generic).
26. Tait B.D., Susal C., Gebel H.M., Nickerson P.W., Zachary A.A., Claas F.H., et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013, 95:19-47.
27. Tambur A.R., Leventhal J.R., Zitzner J.R., Walsh R.C., Friedewald J.J. The DQ barrier: improving organ allocation equity using HLA-DQ information. Transplantation 2013, 95:635-640.